Suppr超能文献

衰老骨骼与骨质疏松症:预防老年人骨折的策略

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

作者信息

Ettinger Mark P

机构信息

Regional Osteoporosis Center of South Florida and Radiant Research Stuart Florida, Stuart 34996, USA.

出版信息

Arch Intern Med. 2003 Oct 13;163(18):2237-46. doi: 10.1001/archinte.163.18.2237.

Abstract

As the older population increases, the incidence of osteoporotic fractures is expected to dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any given bone mineral density (BMD) than are younger patients because of various factors, including the quality of aging bone, which involves more than BMD. Suppression of increased bone turnover by antiresorptive therapies, even with only small changes in BMD, can reduce fracture risk, especially in the lumbar spine. Bisphosphonate treatment can significantly reduce vertebral and nonvertebral fractures, including hip fractures, even in the very elderly. Prospective analyses show that risedronate therapy consistently and significantly reduces the risk of new morphometric vertebral fractures after 1 year in postmenopausal women. Post hoc analyses report significant reductions in the risk of 1 new clinical vertebral fracture after 6 months of risedronate therapy and after 1 year of alendronate therapy. Oral raloxifene therapy and salmon calcitonin nasal spray therapy have been shown to reduce the risk of vertebral fracture after 3 and 5 years, respectively, and post hoc data show a significant reduction in clinical vertebral fracture risk at 1 year with raloxifene use. However, neither raloxifene therapy nor calcitonin therapy reduce the risk of nonvertebral and hip fractures at currently approved doses. Bisphosphonates have been shown to be safe and efficacious with 7 years' risedronate sodium and 10 years' alendronate sodium data published, and bisphosphonates reduce bone turnover and increase BMD to a greater degree than raloxifene and calcitonin, which may partly account for their nonvertebral and hip fracture reduction effect. Therefore, bisphosphonate therapy with risedronate or alendronate should be considered in patients with low BMD at the hip and in older patients with osteoporosis and osteopenia, particularly those with an existing fracture.

摘要

随着老年人口的增加,预计在未来几十年骨质疏松性骨折的发生率将急剧上升。由于多种因素,包括老化骨骼的质量(这不仅仅涉及骨密度),在任何给定的骨矿物质密度(BMD)下,老年患者比年轻患者更容易发生骨折。抗吸收疗法抑制骨转换增加,即使骨密度只有很小的变化,也可以降低骨折风险,尤其是在腰椎。双膦酸盐治疗可以显著降低椎体和非椎体骨折的风险,包括髋部骨折,即使是在非常年老的患者中。前瞻性分析表明,利塞膦酸盐治疗在绝经后妇女中1年后持续且显著降低新的形态计量学椎体骨折的风险。事后分析报告称,利塞膦酸盐治疗6个月后以及阿仑膦酸盐治疗1年后,新的临床椎体骨折风险显著降低。口服雷洛昔芬治疗和鲑鱼降钙素鼻喷雾剂治疗分别在3年和5年后显示可降低椎体骨折风险,事后数据显示使用雷洛昔芬1年后临床椎体骨折风险显著降低。然而,按照目前批准的剂量,雷洛昔芬治疗和降钙素治疗均不能降低非椎体和髋部骨折的风险。已公布的7年利塞膦酸钠和10年阿仑膦酸钠数据表明双膦酸盐是安全有效的,并且双膦酸盐比雷洛昔芬和降钙素更能降低骨转换并增加骨密度,这可能部分解释了它们降低非椎体和髋部骨折的效果。因此,对于髋部骨密度低的患者以及患有骨质疏松症和骨质减少症的老年患者,尤其是那些已有骨折的患者,应考虑使用利塞膦酸盐或阿仑膦酸盐进行双膦酸盐治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验